Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways

British Journal of Pharmacology

Volumn 162, Issue 1, 2011, Pages 286-294

  Ledgerwood, C J ^a   Greenwood, S M ^a   Brett, R R ^a   Pratt, J A ^a   Bushell, T J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

5 HT 1A; cannabidiol; CB 1; hippocampus; synaptic transmission

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; HIPPOCAMPUS; IN VITRO STUDY; INHIBITION KINETICS; NERVE CELL CULTURE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION;

ANIMALS; CANNABIDIOL; CELLS, CULTURED; HIPPOCAMPUS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; SYNAPTIC TRANSMISSION;

EID: 78650145243     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01015.x     Document Type: Article

References (46)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Andrade R, Nicoll RA, (1987). Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. J Physiol 394: 99-124.
3. Bajo M, Roberto M, Schweitzer P, (2009). Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands. J Neurosci Res 87: 766-775.
4. Baskys A, Malenka RC, (1991). Agonists at metabotropic glutamate receptors presynaptically inhibit EPSCs in neonatal rat hippocampus. J Physiol 444: 687-701.
5. Ben Amar M, (2006). Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 105: 1-25.
6. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O' Carroll CM, et al. (2009). Modulation of mediotemporal and ventrostriatal function in humans by Delta-9-Tetrahydrocannabinol. Arch Gen Psychiatry 66: 442-451.
7. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764-774.
8. Billups B, Forsythe ID, (2002). Presynaptic mitochondrial calcium sequestration influences transmission at mammalian central synapses. J Neurosci 22: 5840-5847.
9. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
10. Campos AC, Guimarães FS, (2008). Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 199: 223-230.
11. Catterall WA, (2000). Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16: 521-555.
12. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. (2008). Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33: 2505-2516.
13. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, et al. (2008). Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325: 1007-1015.
14. Drysdale AJ, Ryan D, Pertwee RG, Platt B, (2006). Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology 50: 621-631.
15. Fitzjohn SM, Collingridge GL, (2002). Calcium stores and synaptic plasticity. Cell Calcium 32: 405-411.
16. Fletcher PC, Honey GD, (2006). Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits. Trends Cogn Sci 10: 167-174.
17. Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S, et al. (2009). Modulation of effective connectivity during emotional processing by Delta9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 24: 1-12.
18. Greenwood SM, Mizielinska SM, Frenguelli BG, Harvey J, Connolly CN, (2007). Mitochondrial dysfunction and dendritic beading during neuronal toxicity. J Biol Chem 282: 26235-26244.
19. Hashimotodani Y, Ohno-Shosaku T, Kano M, (2007). Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J Neurosci 27: 1211-1219.
20. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
21. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. (2010). Cannabidiol displays anti-epileptiform and anti-seizure properties in vitro and in vivo. J Pharmacol Exp Ther 332: 569-577.
22. Le Magueresse C, Cherubini E, (2007). Presynaptic calcium stores contribute to nicotine-elicited potentiation of evoked synaptic transmission at CA3-CA1 connections in the neonatal rat hippocampus. Hippocampus 17: 316-325.
23. Lüscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA, (1997). Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. Neuron 19: 687-695.
24. Ohno-Shosaku T, Hashimotodani Y, Maejima T, Kano M, (2005). Calcium signaling and synaptic modulation: regulation of endocannabinoid-mediated synaptic modulation by calcium. Cell Calcium 38: 369-374.
25. Pertwee RG, (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76: 1307-1324.
26. Pertwee RG, (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
27. Premkumar LS, Gage PW, (1994). Potassium channels activated by GABAB agonists and serotonin in cultured hippocampal neurons. J Neurophysiol 71: 2570-2575.
28. Pugliese AM, Passani MB, Corradetti R, (1998). Effect of the selective 5-HT1A receptor antagonist WAY100135 on the inhibition of e.p.s.ps produced by 5-HT in the CA1 region of rat hippocampal slices. Br J Pharmacol 124: 93-100.
29. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM, (2008). TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28: 6231-6238.
30. Rakhshan F, Day TA, Blakely RD, Barker EL, (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. J Pharmacol Exp Ther 292: 960-967.
31. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Corrêa FM, Guimarães FS, (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181-188.
32. Roloff AM, Thayer SA, (2009). Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate. Mol Pharmacol 75: 892-900.
33. Ross HR, Napier I, Connor M, (2008). Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem 283: 16124-16134.
34. Russo E, Guy GW, (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246.
35. Russo EB, Burnett A, Hall B, Parker KK, (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043.
36. Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B, (2009). Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci 29: 2053-2063.
37. Schmitz D, Empson RM, Heinemann U, (1995). Serotonin reduces inhibition via 5-HT1A receptors in area CA1 of rat hippocampal slices in vitro. J Neurosci 15: 7217-7225.
38. Schmitz D, Gloveli T, Empson RM, Heinemann U, (1998). Comparison of the effects of serotonin in the hippocampus and the entorhinal cortex. Mol Neurobiol 17: 59-72. (Pubitemid 29030731)
39. Shen M, Thayer SA, (1999). Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55: 8-13.
40. Showalter VM, Compton DR, Martin BR, Abood ME, (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278: 989-999.
41. Straiker A, Mackie K, (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569: 501-517.
42. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG, (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 150: 613-623.
43. Turcotte D, Le Dorze JA, Esfahani F, Frost E, Gomori A, Namaka M, (2010). Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother 11: 17-31.
44. Wheeler DB, Randall A, Tsien RW, (1994). Roles of N-type and Q-type Ca2+ channels in supporting hippocampal synaptic transmission. Science 264: 107-111.
45. Yakel JL, Trussell LO, Jackson MB, (1988). Three serotonin responses in cultured mouse hippocampal and striatal neurons. J Neurosci 8: 1273-1285.
46. Zanelati T, Biojone C, Moreira F, Guimarães F, Joca S, (2010). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT receptors. Br J Pharmacol 159: 122-128.